biotech
biotech Articles
One industry that could be a huge winner from tax reform, and may surprise some investors, is biotechnology, especially for the large cap leaders in the group.
Published:
Last Updated:
Denali Therapeutics entered the markets with a bang on Friday. In its initial public offering, the company priced its almost 14 million shares within the expected range.
Published:
Last Updated:
Radius Health shares climbed higher on Friday after the firm provided an update on its early-stage clinical study in patients with estrogen receptor positive breast cancer.
Published:
Last Updated:
SteadyMed saw its shares make an incredibly gain to close out the week, after a positive meeting with the FDA.
Published:
Last Updated:
Alexion Pharmaceuticals shares saw a handy gain early on Friday after the New York Times reported that there might be some increasing activist movement in the stock.
Published:
Last Updated:
Sage Therapeutics saw its shares make an incredible gain on Thursday after the firm announced positive top-line results from its midstage trial.
Published:
Last Updated:
Arrowhead Pharmaceuticals saw its shares make a handy gain on Wednesday after the firm presented new data from its midstage study for the treatment of hepatitis B infection.
Published:
Last Updated:
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
Published:
Last Updated:
Shares of Revance Therapeutics saw a solid gain early on Tuesday after the company announced positive top-line results from its late-stage trials.
Published:
Last Updated:
These four momentum biotech plays still have solid upside to the Jefferies price targets and would be solid additions to aggressive accounts with higher risk tolerance.
Published:
Last Updated:
Life sciences company Quanterix intends to price more than 3 million shares for an initial public offering valued up to more than $61 million.
Published:
Last Updated:
Odonate Therapeutics expects to price more than 5 million shares in a range that results in an initial public offering valued up to more than $182 million.
Published:
Last Updated:
Alkermes saw its shares make a handy gain to start off the week, after the firm announced that it has entered into a global license agreement with Biogen.
Published:
Last Updated:
Neurodegenerative disease focused Denali Therapeutics intends to price more than 8 million shares in a range that results in an initial offering valued up to about $182 million.
Published:
Last Updated:
Celsion Corp. (NASDAQ: CLSN) watched its shares make an incredible gain on Tuesday after it received an even bigger upgrade from Oppenheimer. This came on the heels of new findings in its Liver...
Published:
Last Updated: